Cognition Therapeutics, Inc. (CGTX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 39/100 (MEDIUM), 16.1 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 9.46% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
- Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates
- Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
- Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
- Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33%
- Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX)
- Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
- Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- A meta-analysis of the effects of combined interventions centered on cognitive training on cognition, executive function, and negative emotions in patients with Alzheimer's disease. — Front Neurol 2026 PMID 42812254
- Longitudinal Changes in Hippocampal-Default Mode Network Connectivity and Cognition During Electroacupuncture Intervention in Type 2 Diabetes-Associated Cognitive Decline: A Pilot Resting-State fMRI Study. — J Integr Neurosci 2026 Sep 21 PMID 42811891
- Brain-cognition relationships and treatment outcome in treatment-resistant late-life depression. — Nat Commun 2026 Aug 29 PMID 42811009
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Cognition Therapeutics, Inc..
Full CGTX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.